Clot-busting drug on target

The new therapy works by fusing an existing blood-clot busting drug to an antibody specifically targeted to activated platelets that are part of the clotting system. This novel approach allows the drug to specifically target the area where the vessel is blocked, unlike existing treatments that work on the whole circulatory system. 

Research lead, Dr Christoph Hagemeyer, Head of the Vascular Biotechnology Laboratory at Baker IDI Heart and Diabetes Institute, said the treatment offers a safer drug with fewer side effects.

“Because our drug is targeted, we were able to administer it at six times less concentrated dose than existing treatments. So we don’t have the systemic side effects such as bleeding – making it a much safer treatment.”

In preclinical studies, the drug had an observed effect within 10 minutes of administration with the clot completely removed after 40 mins and the six-fold less concentrated dose